Soracom Expands Global IoT Partner Program in Europe & Americas
11.5.2022 15:00:00 EEST | Business Wire | Press release
Soracom, Inc., a global provider of advanced IoT connectivity, today announced the expansion of its Soracom Partner Space program to new members throughout the Americas and Europe. The program now reaches more than 800 best-in-class members throughout the world, including more than 100 certified partners representing hardware, software, solutions and integration services. The addition of these members will help IoT innovators accelerate time to market with as-needed access to complementary, best-in-class solutions and services that are ready to integrate at every level of the IoT stack.
The Soracom Partner Space enables partners to access live opportunities and technical collaborations to provide services to IoT innovators around the world. In turn, customers are able to find trusted partners who will help them bring solutions to market and scale more quickly, create differentiators, and simplify the IoT journey.
Supporting 4 million connections with global IoT coverage in more than 160 countries, Soracom offers a portfolio of powerful connectivity solutions that help IoT deployments connect securely and easily to leading hyperscaler platforms, reduce data and power requirements, and manage total cost of ownership at scale. Soracom Partner Space partners have supported many of the projects behind Soracom’s expansion.
“Collaborating with industry-leading partners to connect millions of devices worldwide, Soracom understands deeply that success in IoT depends on the specialized tools and expertise that only a complete ecosystem can provide,” said Alexis Susset, Soracom vice president of global product and EU sales. “We are thrilled to expand our global partner program to help more customers bring successful solutions to market and scale quickly across Europe and around the world.”
Today, partners in the Americas and EU include:
- AI Dynamics
- Balena
- BDATA
- CalChip Connect
- Cassia Networks
- Converge IoT
- Esper
- IoThink Solutions
- NeuronicWorks
- Prescient Devices
- Quake Global
- Seeed Studio
- SGS
- SpaceSense Systems
- ST
- Teltonika Networks and Telematics
- Thinxtra
- uHoo
- UnaBiz
"UnaBiz has connected over 1M devices with Soracom and that number is fast-growing," said Yadia Colindres, deputy CTO at UnaBiz. "With this global partnership, UnaBiz will be sharing its ideation, production, deployment and maintenance experience and services in Massive IoT with the entire Soracom ecosystem, to help IoT solution providers and operators to scale quickly and with confidence."
“Over 3,000 professionals use IoThink Solutions' IoT platform, KHEIRON IoT Suite, to monitor and control connected devices, and analyze data all around the world,” said Julien Dalmasso, CEO at IoThink Solutions. “Like Soracom, we believe in open and interoperable platforms to serve customers across various industries, from Smart Building to Smart Industry, Smart Energy or even Smart City. We look forward to working together to assist builders and help integrators design and deploy a new generation of IoT use cases.”
For more information on the Soracom Partner Space program and to apply, visit: soracom.io/partners
About Soracom
Soracom is leading the democratization of IoT connectivity, offering robust solutions specifically designed to make it easy to build, operate, and scale IoT deployments. Founded in 2015, Soracom now serves more than 20,000 startups, SMBs and global enterprises across all industries, from agriculture, energy, construction and transportation to consumer electronics, manufacturing, real estate and healthcare. Customers trust Soracom for affordable, reliable connectivity that accelerates speed to market, makes it easy to connect to the cloud, and offers access to a worldwide partner ecosystem. More information is available at www.soracom.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005206/en/
Contact information
Justine Schneider
Calysto Communications
jschneider@calysto.com
O: 404-266-2060, ext. 507
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom